Aura Biosciences (NASDAQ:AURA) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Aura Biosciences (NASDAQ:AURA) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $19.00 target price on the stock.

Separately, HC Wainwright initiated coverage on shares of Aura Biosciences in a research report on Thursday, July 25th. They issued a buy rating and a $21.00 target price on the stock.

Aura Biosciences Stock Up 1.3 %

NASDAQ AURA opened at $7.73 on Wednesday. The firm has a market capitalization of $382.97 million, a PE ratio of -4.16 and a beta of 0.40. The stock’s 50 day moving average is $8.22 and its 200 day moving average is $7.90. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.35.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. American Century Companies Inc. bought a new position in Aura Biosciences in the 2nd quarter valued at approximately $119,000. Trexquant Investment LP lifted its holdings in shares of Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock valued at $154,000 after purchasing an additional 6,809 shares in the last quarter. American International Group Inc. boosted its position in shares of Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after buying an additional 3,782 shares during the last quarter. Virtu Financial LLC bought a new stake in Aura Biosciences in the 1st quarter worth about $144,000. Finally, TBH Global Asset Management LLC increased its holdings in Aura Biosciences by 82.3% in the 4th quarter. TBH Global Asset Management LLC now owns 60,322 shares of the company’s stock worth $534,000 after buying an additional 27,225 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.